-
-
-
-
-
-
-
Trump to unveil more discounted prescription drug options - CNBC
-
-
-
-
-
-
-
AbbVie (ABBV) Tops Q1 EPS by 6c, Beats on Revenue; Offers FY26 EPS Guidance
-
-
-
-
-
-
-
Canaccord Starts Abbvie (ABBV) at Buy, PT set at $262
-
-
-
-
-
-
-
RBC Capital on Biopharma: 'M&A Discussion, Whether Accurate Or Not, Can Drive Returns'
-
-
-
-
-
-
-
Barclays Starts Abbvie (ABBV) at Overweight
-
-
-
-
-
-
-
AbbVie beats Q4 expectations, shares dip
-
-
-
-
-
-
-
This U.S. biotech stock is Bernstein's Top Pick for 2026
-
413,572 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

